Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform

Author's Avatar
Jun 22, 2022

Comera+Life+Sciences+Holdings%2C+Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore™ platform as viscosity-lowering agents to significantly optimize filtration efficiency of protein solutions during the biologics manufacturing process. The ‘857 patent reflects a significant addition to Comera’s current intellectual property portfolio and expands the potential commercial applications of SQore, broadening patent protections beyond use in therapeutic antibody formulations to include manufacturing process enhancement.